skip to main content


Title: Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain

Selegiline (L-deprenyl) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) at the conventional dose (10 mg/day oral) that is used in the treatment of Parkinson’s disease. However, controlled studies have demonstrated antidepressant activity for high doses of oral selegiline and for transdermal selegiline suggesting that when plasma levels of selegiline are elevated, brain MAO-A might also be inhibited. Zydis selegiline (Zelapar®) is an orally disintegrating formulation of selegiline, which is absorbed through the buccal mucosa producing higher plasma levels of selegiline and reduced amphetamine metabolites compared to equal doses of conventional selegiline. Although there is indirect evidence that Zydis selegiline at high doses loses its selectivity for MAO-B, there is no direct evidence that it also inhibits brain MAO-A in humans. We measured brain MAO-A in 18 healthy men after a 28-day treatment with Zydis selegiline (2.5, 5.0, or 10 mg/day) and in 3 subjects receiving the selegiline transdermal system (Emsam patch, 6 mg/day) using PET and the MAO-A radiotracer [¹¹C]clorgyline. We also measured dopamine transporter (DAT) availability in three subjects from the 10 mg group. The 10 mg Zydis selegiline dose significantly inhibited MAO-A (36.9 ± 19.7%, range 11–70%, p<0.007)) but not DAT; and while Emsam alsomore » inhibited MAO-A (33.2 ± 28.9 (range 9-68%) the difference did not reach significance (p=0.10)) presumably because of the small sample size. Our results provide the first direct evidence of brain MAO-A inhibition in humans by formulations of selegiline, which are currently postulated but not verified to target brain MAO-A in addition to MAO-B.« less
 [1] ;  [2] ;  [3] ;  [4] ;  [5] ;  [6] ;  [4] ;  [4] ;  [1] ;  [4] ;  [1] ;  [1] ;  [1] ;  [6] ;  [4] ;  [1] ;  [1] ;  [4]
  1. Brookhaven National Lab. (BNL), Upton, NY (United States)
  2. New York Univ., NY (United States)
  3. National Inst. on Drug Abuse, Bethesda, MD (United States); National Inst. on Alcohol Abuse and Alcoholism, Bethesda, MD (United States)
  4. National Inst. on Alcohol Abuse and Alcoholism, Bethesda, MD (United States)
  5. Targeted Medical Pharma Inc., Los Angeles, CA (United States)
  6. Columbia Univ., New York, NY (United States)
Publication Date:
Report Number(s):
Journal ID: ISSN 0893-133X; R&D Project: MO-085; KP1602010
Grant/Contract Number:
Accepted Manuscript
Journal Name:
Additional Journal Information:
Journal Volume: 40; Journal Issue: 3; Journal ID: ISSN 0893-133X
Research Org:
Brookhaven National Laboratory (BNL), Upton, NY (United States)
Sponsoring Org:
USDOE Office of Science (SC), Biological and Environmental Research (BER) (SC-23)
Country of Publication:
United States
38 RADIATION CHEMISTRY, RADIOCHEMISTRY, AND NUCLEAR CHEMISTRY; brain MAO-A; MAO inhibitors; PET; selegiline; Zydis selegiline; Emsam; selegiline transdermal system; buccal mucosa absorption; positron emission tomography (PET) facility
OSTI Identifier: